Views & Analysis Tunnah’s musings: Rare diseases hold key to future of drug d... The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.
Views & Analysis Rethinking rare diseases: treat the whole patient CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.
News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.